Platforms

Superkine™

Medicenna's Superkine™ creates Superkines - interleukins that have been engineered to deliver properties that natural interleukins cannot achieve. Through directed evolution we generate libraries of IL-2, IL-4 and IL-13 Superkines that are optimised for receptor selectivity, potency, half-life and tissue distribution. Our Superkines precisely modulate interleukin communication networks to shape the fate of the cells receiving the signals, and ultimately achieve desired therapeutic outcomes.

BiSKIT™

(Bi-functional SuperKine Immuno-Therapy)

Why select just one target when you can select two? Our BiSKIT™ (Bi-functional SuperKine Immuno-Therapy) platform works by fusing Superkines with antibodies, other proteins or even a second Superkine to allow for modulation of two synergistic signaling pathways at the same time. The outcome is improved immune system control. We prevent immune cells from becoming exhausted, while keeping disease-fighting cells active.

T-MASK™

(Targeted Metallo-protease Activated SuperKines)

T-MASK™ (Targeted Metallo-protease Activated SuperKines): T-MASK™ adds another layer of precision: where and when our therapies are active. T-MASK therapies are designed to stay switched off while they travel through the body. They carry a temporary mask that blocks their activity in healthy tissues. At the site of disease (for example a tumor) disease-related enzymes cut off this mask. Once the mask is removed, the therapy is switched on locally, so the drug becomes active only where it is needed most.